Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 11, 2011, Pages 2951-2957

  Xu, Chengfang ^a   Li, Xiaomao ^a   Li, Tian ^a   Wang, Xiaoyun ^a   Yang, Yuebo ^a   Xiao, Lan ^a   Shen, Huimin ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Combination therapy; Endometrial cancer; Inhibitor; Paclitaxel; PI3K AKTpten pathway

Indexed keywords

EID: 84863309809     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Amant F, Moerman P, Neven P, et al (2005). Endometrial cancer. Lancet, 366, 491-505.
2. Asnaghi L, Bruno P, Priulla M, et al (2004). MtorA protein kinase switching between life and death. Pharmacol Res, 50, 545-9.
3. Ball HG, Blessing JA, Lentz SS, et al (1996). A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol, 62, 278-81.
4. Buck E, Eyzaguirre A, Brown E, et al (2006). Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic,colon, and breast tumors. Mol Cancer Ther, 5, 2676-84.
5. Chaturvedi D, Gao X, Cohen MS, et al (2009). Rapamycin induces transactivation of the egfr and increases cell survival. Oncogene, 28, 1187-96.
6. Dancey JE, Chen HX (2006). Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov, 5, 649-59.
7. Dedes KJ, Wetterskog D, Ashworth A, et al (2011). Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol, 8, 261-71.
8. Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al (2010). PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to parp inhibitors. Sci Transl Med, 2, 53-75.
9. de Groot JF, Gilbert MR, Aldape K, et al (2008). Phase ii study of carboplatin and erlotinib (tarcevaosi-774) in patients with recurrent glioblastoma. Dedes KJ, 90, 89-97.
10. Diaz JF, Andreu JM (1993). Assembly of purified gdp-tubulin into microtubules induced by taxol and taxotere: Reversibility, ligand stoichiometry, and competition. Biochemistry, 32, 2747-55.
11. Doherty L, Gigas DC, Kesari S, et al (2006). Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology, 67, 156-8.
12. Faivre S, Kroemer G, Raymond E (2006). Current development of mtor inhibitors as anticancer agents. Nat Rev Drug Discov, 5, 671-88.
13. Hsu CH, Gao M, Chen CL, et al (2005). Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro. Oncology, 68, 538-47.
14. Humber CE, Tierney JF, Symonds RP, et al (2007). Chemotherapy for advanced, recurrent or metastatic endometrial cancer: A systematic review of cochrane collaboration. Ann Oncol, 18, 409-20.
15. Jimeno A, Kulesza P, Wheelhouse J, et al (2007). Dual egfr and mtor targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer, 96, 952-9.
16. Lincoln S, Blessing JA, Lee RB, et al (2003). Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol, 88, 277-81.
17. Masiello D, Mohi MG, McKnight NC, et al (2007) Combining an mtor antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer. Cancer Biol Ther, 6, 195-201.
18. Microrna-21 inhibitor sensitizes human glioblastoma cells u251 (pten-mutant) and ln229 (pten-wild type) to taxol. BMC Cancer, 10, 27.
19. Nakajima H, Mizuta N, Sakaguchi K, et al (2010). Enhancement of paclitaxel-induced apoptosis in her2-overexpressing human breast cancer cells by a pertuzumab mimetic peptidehrap. J Biosci Bioeng, 110, 250-3.
20. Ollikainen M, Gylling A, Puputti M, et al (2007). Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. International J of Cancer, 121, 915-20.
21. Oza AM, Eisenhauer EA, Elit L, et al (2008). Phase ii study of erlotinib in recurrent or metastatic endometrial cancer: Ncic ind-148. J Clin Oncol, 26, 4319-25.
22. Pfeiffer D, Spranger J, Al-Deiri M, et al (1997). MRNA expression of ligands of the epidermal-growth- factor- receptor in the uterus. Int J Cancer, 72, 581-6.
23. Slomovitz BM, Lu KH, Johnston T, et al (2010). A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer, 116, 5415-9.
24. Vignot S, Faivre S, Aguirre D, et al (2005). Mtor-targeted therapy of cancer with rapamycin derivatives. Ann Oncol, 16, 525-37.
25. Wang LH, Chan JL, Li W (2007). Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in erbb2 over expressing breast cancer cells. Int J Cancer, 121, 157-64.
26. Wetterskog D, Mendes-Pereira AM, et al (2010). Pten deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to parp inhibitors. Sci Transl Med, 2, 53-75. Ren Y, Zhou X, Mei M, et al (2010).
27. Xu G, Zhang W, Bertram P, et al (2004).Pharmacogenomic profiling of the pi3k/pten-akt-mtor pathway in common human tumors. Int J Oncol, 24, 893-900.
28. Zuo Q, Shi M, Li L, et al (2010). Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance. Biomed Pharmacother, 64, 550-8